A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome
A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome
Sponsor: Pierre Fabre Medicament
A PHASE3 clinical study on Fibromyalgia Syndrome, this trial is completed. The trial is conducted by Pierre Fabre Medicament and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Feb 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pierre Fabre Medicament
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain, Bucharest, Romania, Cologne, Germany, Frederiksberg, Denmark, Kuopio, Finland, Lillehamer, Norway, Lisbon, Portugal, London, United Kingdom, Milan, Italy, Mölndal, Sweden and 3 more location s